Search
Hengrui Medicine Subsidiary Secures Drug Registration for New Fanicizumab Injection Indication
2025-04-08 /
Read about 0 minute
Author：小编
Hengrui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical, has successfully secured a drug registration certificate for a novel indication of fanicizumab injection. This new indication targets adult patients suffering from active ankylosing spondylitis who have exhibited an inadequate response to conventional therapeutic approaches. Previously, the injection had been authorized for the treatment of adult patients with moderate to severe plaque psoriasis, with a cumulative investment in related research and development amounting to approximately RMB 651 million.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
